Current strategies for the management of locoregional breast cancer recurrence

Irene L. Wapnir, Atif Khan

Research output: Contribution to journalReview article

1 Citation (Scopus)

Abstract

Advances in the treatment of breast cancer have decreased the rate of isolated locoregional recurrences (ILRRs) over time. Surgery, radiation therapy, and systemic therapies are used to manage these failure events and their associatedpoor prognosis. Operable ipsilateral breast tumor recurrences (IBTRs) are treated by either salvage mastectomy or, in selectcases, repeat lumpectomy. Axillary nodal recurrences and postmastectomy chest wall relapses are commonly amenable to surgical resection, too. Repeat sentinel node mapping may be undertaken after IBTRs and chest wall recurrences. Aberrant lymphatic drainage, especially after previous mastectomy, is frequently observed. Adjuvant radiation is recommended for most ILRR cases; the dose and volume must be adjusted for prior to receipt of therapy. Implementation of adjuvant systemic therapies after ILRR should be based on the expression of molecular markers in the recurrent tumor. Administration of chemotherapy for estrogen receptor�negative ILRR is indicated, since it significantly decreases the rate of distant metastases.

Original languageEnglish (US)
Pages (from-to)19-25
Number of pages7
JournalONCOLOGY (United States)
Volume33
Issue number1
StatePublished - Jan 1 2019

Fingerprint

Breast Neoplasms
Recurrence
Mastectomy
Thoracic Wall
Segmental Mastectomy
Therapeutics
Drainage
Estrogens
Radiotherapy
Radiation
Neoplasm Metastasis
Drug Therapy
Neoplasms

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Wapnir, Irene L. ; Khan, Atif. / Current strategies for the management of locoregional breast cancer recurrence. In: ONCOLOGY (United States). 2019 ; Vol. 33, No. 1. pp. 19-25.
@article{f378bb807d024be29ae40e0c49c03928,
title = "Current strategies for the management of locoregional breast cancer recurrence",
abstract = "Advances in the treatment of breast cancer have decreased the rate of isolated locoregional recurrences (ILRRs) over time. Surgery, radiation therapy, and systemic therapies are used to manage these failure events and their associatedpoor prognosis. Operable ipsilateral breast tumor recurrences (IBTRs) are treated by either salvage mastectomy or, in selectcases, repeat lumpectomy. Axillary nodal recurrences and postmastectomy chest wall relapses are commonly amenable to surgical resection, too. Repeat sentinel node mapping may be undertaken after IBTRs and chest wall recurrences. Aberrant lymphatic drainage, especially after previous mastectomy, is frequently observed. Adjuvant radiation is recommended for most ILRR cases; the dose and volume must be adjusted for prior to receipt of therapy. Implementation of adjuvant systemic therapies after ILRR should be based on the expression of molecular markers in the recurrent tumor. Administration of chemotherapy for estrogen receptor�negative ILRR is indicated, since it significantly decreases the rate of distant metastases.",
author = "Wapnir, {Irene L.} and Atif Khan",
year = "2019",
month = "1",
day = "1",
language = "English (US)",
volume = "33",
pages = "19--25",
journal = "Oncology",
issn = "0890-9091",
publisher = "UBM Medica Healthcare Publications",
number = "1",

}

Current strategies for the management of locoregional breast cancer recurrence. / Wapnir, Irene L.; Khan, Atif.

In: ONCOLOGY (United States), Vol. 33, No. 1, 01.01.2019, p. 19-25.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Current strategies for the management of locoregional breast cancer recurrence

AU - Wapnir, Irene L.

AU - Khan, Atif

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Advances in the treatment of breast cancer have decreased the rate of isolated locoregional recurrences (ILRRs) over time. Surgery, radiation therapy, and systemic therapies are used to manage these failure events and their associatedpoor prognosis. Operable ipsilateral breast tumor recurrences (IBTRs) are treated by either salvage mastectomy or, in selectcases, repeat lumpectomy. Axillary nodal recurrences and postmastectomy chest wall relapses are commonly amenable to surgical resection, too. Repeat sentinel node mapping may be undertaken after IBTRs and chest wall recurrences. Aberrant lymphatic drainage, especially after previous mastectomy, is frequently observed. Adjuvant radiation is recommended for most ILRR cases; the dose and volume must be adjusted for prior to receipt of therapy. Implementation of adjuvant systemic therapies after ILRR should be based on the expression of molecular markers in the recurrent tumor. Administration of chemotherapy for estrogen receptor�negative ILRR is indicated, since it significantly decreases the rate of distant metastases.

AB - Advances in the treatment of breast cancer have decreased the rate of isolated locoregional recurrences (ILRRs) over time. Surgery, radiation therapy, and systemic therapies are used to manage these failure events and their associatedpoor prognosis. Operable ipsilateral breast tumor recurrences (IBTRs) are treated by either salvage mastectomy or, in selectcases, repeat lumpectomy. Axillary nodal recurrences and postmastectomy chest wall relapses are commonly amenable to surgical resection, too. Repeat sentinel node mapping may be undertaken after IBTRs and chest wall recurrences. Aberrant lymphatic drainage, especially after previous mastectomy, is frequently observed. Adjuvant radiation is recommended for most ILRR cases; the dose and volume must be adjusted for prior to receipt of therapy. Implementation of adjuvant systemic therapies after ILRR should be based on the expression of molecular markers in the recurrent tumor. Administration of chemotherapy for estrogen receptor�negative ILRR is indicated, since it significantly decreases the rate of distant metastases.

UR - http://www.scopus.com/inward/record.url?scp=85069498225&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85069498225&partnerID=8YFLogxK

M3 - Review article

C2 - 30731014

AN - SCOPUS:85069498225

VL - 33

SP - 19

EP - 25

JO - Oncology

JF - Oncology

SN - 0890-9091

IS - 1

ER -